Pharma BD Deal Intelligence
Salix's ~$2.6B cash buyout of Santarus imploded fast: within 15 months Salix itself was swallowed by Valeant amid a wholesaler inventory-stuffing scandal, and Santarus-origin Glumetza later triggered a $454M pay-for-delay antitrust settlement.
The combined entity will be a GI-focused powerhouse with 22 marketed products, pro-forma revenues of $1.348B and adjusted EBITDA of $537M.
Execution risk centers on marketing Glumetza and Ruconest outside the core GI call point; integration of Santarus's primary-care reps will be the swing factor.
A value-creating deal that diversifies Salix's revenue base; Uceris alone with $400-700M peak potential could justify approximately two-thirds of the purchase…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Salix acquired Santarus at $32/share cash (~$2.6B; 36% premium); expanded Salix's GI portfolio and added primary care/diabetes assets; financed via $800M cash + $1.95B Jefferies committed debt.
Assessment window: 5yr post-close.
Ulcerative colitis is a chronic inflammatory bowel disease causing continuous mucosal inflammation of the colon and rectum, presenting with bloody diarrhea, urgency, and abdominal pain. It typically onsets in young adulthood, follows a relapsing-remitting course, and increases colorectal cancer risk; treatment is lifelong with mesalamine, corticosteroids, immunomodulators, and biologics.
At deal time the UC induction market was anchored by 5-ASAs (Asacol HD, Lialda, Apriso, Pentasa) for mild-moderate disease and biologics (Remicade/infliximab, Humira/adalimumab) for moderate-severe disease. Santarus's Uceris (budesonide MMX) launched February 2013 as a once-daily oral steroid with colon-targeted release, offering a steroid-sparing induction option with reduced systemic exposure versus prednisone — a meaningful differentiation in the mild-moderate segment dominated by 5-ASAs. Salix's $2.6B acquisition (~7x estimated 2013 sales of $370M) was structurally driven by reducing dependence on Xifaxan (~two-thirds of Salix revenue) and absorbing Santarus's complementary primary-care/diabetes assets (Glumetza, Zegerid, Cycloset, Fenoglide). Analysts at Stifel and Motley Fool argued Uceris alone justified ~two-thirds of the purchase price, with peak potential of $400-700M; the Salix sales force was expected to accelerate Uceris uptake by leveraging existing GI relationships. The combined company became the dominant US specialty GI player with 22 marketed products and pro-forma revenues of $1.348B and adjusted EBITDA of $537M. Salix was itself acquired by Valeant in 2015 for $14.5B.
Type 2 diabetes is a progressive metabolic disorder characterized by insulin resistance and relative insulin deficiency, leading to hyperglycemia and cardiovascular, renal, and microvascular complications. It affects roughly 1 in 8 US adults; metformin remains first-line therapy, with extended-release formulations preferred for tolerability.
The 2013 type 2 diabetes oral therapy market was dominated by generic metformin IR, with extended-release options (Glucophage XR generics, Glumetza, Fortamet) holding a smaller premium-priced segment. Glumetza (metformin HCl ER) used Depomed's gastric-retentive AcuForm technology to deliver once-daily metformin with improved GI tolerability over IR formulations. Cycloset (bromocriptine mesylate) was a niche dopamine agonist with limited uptake against the broader DPP-4/SGLT2 wave (Januvia, Invokana, Farxiga). Salix's strategic challenge in acquiring these assets was that they sat outside the core GI call point — analysts (Motley Fool, Seeking Alpha) flagged execution risk in marketing Glumetza and Ruconest to non-GI prescribers without building a parallel sales infrastructure. Glumetza nonetheless contributed >40% of Santarus's projected 2013 revenue, providing meaningful near-term cash flow to support deal financing. Glumetza later faced authorized-generic competition and pricing scrutiny under Valeant ownership.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Salix Pharmaceuticals / Santarus Inc. (this deal) | 2013 | $2.6B | 29 |
| Salix Pharmaceuticals / Oceana Therapeutics, Inc. | 2011 | $300M | 29 |
| UCB SA / Celltech Group plc | 2004 | $2.7B | 92 |
| Johnson & Johnson / Centocor Inc. | 1999 | $4.9B | 92 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2003 | $8.8B | 82 |
| Bristol-Myers Squibb Company / Celgene Corporation | 2019 | $74.0B | 77 |
| Biogen Idec Inc. / Elan Corporation plc (Tysabri rights) | 2013 | $3.2B | 77 |
← Browse all deals · How we score deals
More: 2013 deals · Gastroenterology deals